J. Sieper
- Rheumatology top 0.5%
- Rheumatoid Arthritis Research and Therapies 60
- Spondyloarthritis Studies and Treatments 57
- Systemic Lupus Erythematosus Research 9
- Hematology top 2%
- Autoimmune and Inflammatory Disorders Research 9
- Immunology top 5%
- Psoriasis: Treatment and Pathogenesis 17
-
- Bone and Joint Diseases 10
- Dermatology top 5%
-
- Spine and Intervertebral Disc Pathology 6
-
- Fibromyalgia and Chronic Fatigue Syndrome Research 4
- Co-authors
- Anna Katharina SimonEva SeipeltJürgen BraunHildrun HaibelM. BollowJ. BrandtU. EggensWolfgang Thriene
- Cited by
- RheumatologyHematologyImmunology
- Journals
- Annals of the Rheumatic Diseases (25 papers)Clinical and Experimental Rheumatology (5 papers)Lara D. Veeken (4 papers)
- Partner nations
- GermanyUnited StatesCanada
In The Last Decade
J. Sieper
78 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 87
- Rheumatology 1.7k
- Hematology 611
- Immunology 897
- Orthopedics and Sports Medicine 223
- Dermatology 96
Countries citing papers authored by J. Sieper
This map shows the geographic impact of J. Sieper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Sieper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Sieper more than expected).
Fields of papers citing papers by J. Sieper
This network shows the impact of papers produced by J. Sieper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Sieper. The network helps show where J. Sieper may publish in the future.
Co-authorship network
The 25 scholars most cited alongside J. Sieper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 1 | |
| 4 | Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies | 2017 | 0 |
| 5 | LONG-TERM EFFICACY AND TOLERABILITY OF GOLIMUMAB IN ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS : RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY | 2016 | 1 |
| 6 | Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis | 2014 | 3 |
| 7 | LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL | 2014 | 1 |
| 8 | Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. | 2014 | 1 |
| 9 | CLINICAL RESPONSE AND REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AFTER THREE YEARS OF ADALIMUMAB THERAPY | 2014 | 2 |
| 10 | SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH POSITIVE MRI OF THE SACROILIAC JOINTS OR SPINE OR ELEVATED C-REACTIVE PROTEIN AT BASELINE | 2013 | 1 |
| 11 | Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis : A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks | 2013 | 3 |
| 12 | Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B) | 2012 | 2 |
| 13 | Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis. | 2012 | 4 |
| 14 | Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study | 2012 | 10 |
| 15 | Concurrent sacroiliac joint and spinal inflammation on Mri in patients with non-radiographic axial spondyloarthritis | 2012 | 1 |
| 16 | Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis - Results From a Phase 3 Study | 2011 | 6 |
| 17 | Description of spinal MRI lesions and definition of a positive MRI of the spine in axial SpA | 2010 | 3 |
| 18 | Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS) | 2008 | 2 |
| 19 | Die glukokortikoidinduzierte Osteoporose | 2001 | 2 |
| 20 | 2001 | 78 |
About J. Sieper
J. Sieper is a scholar working on Rheumatology, Orthopedics and Sports Medicine and Immunology, having authored 84 papers that have together received 2.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (60 papers), Spondyloarthritis Studies and Treatments (57 papers), Psoriasis: Treatment and Pathogenesis (17 papers), Bone and Joint Diseases (10 papers), Autoimmune and Inflammatory Disorders Research (9 papers), Systemic Lupus Erythematosus Research (9 papers), Spine and Intervertebral Disc Pathology (6 papers) and Fibromyalgia and Chronic Fatigue Syndrome Research (4 papers). The work is most often cited by research in Rheumatology (1.7k citations), Hematology (611 citations) and Immunology (897 citations). J. Sieper has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Anna Katharina Simon, Eva Seipelt, Jürgen Braun, Jürgen Braun, Hildrun Haibel, M. Bollow, J. Brandt, U. Eggens, Wolfgang Thriene and J. González. Their work appears in journals such as Annals of the Rheumatic Diseases, Clinical and Experimental Rheumatology, Lara D. Veeken, Immunology Letters and Osteoporosis International.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.